“A Review on FDA Approval of Lymphoma Drug Ukoniq (Umbralisib) And Its Withdrwal Due to Safety Concerns ”, Journal of Pharmaceutical Negative Results, vol. 13, no. 4, pp. 1465–1474, Dec. 2022, doi: 10.47750/pnr.2022.13.04.206.